XML 37 R25.htm IDEA: XBRL DOCUMENT
v3.19.2

Assets and Liabilities Measured at Fair Value (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2019
Fair Value Disclosures [Abstract] |
Summary of assets and liabilities subject to fair value measurements | A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of June 30, 2019 are identified in the following table:
(in thousands) |  | Level 2 |  | Total
Assets: |  |  |  |  |  |
Commercial paper |  | $ | 112,026 |  |  | $ | 112,026 |
Asset-backed securities |  | 73,093 |  |  | 73,093 |
Corporate debt securities |  | 169,558 |  |  | 169,558 |
Money market funds |  | 4,224 |  |  | 4,224 |
|  | $ | 358,901 |  |  | $ | 358,901 |
|  | Level 2 |  | Level 3 |  | Total
Liabilities: |  |  |  |  |  |  |  |  |
Contingent consideration payable |  | $ | — |  |  | $ | 21,247 |  |  | $ | 21,247 |
Deferred compensation plan liability |  | 3,874 |  |  | — |  |  | 3,874 |
|  | $ | 3,874 |  |  | $ | 21,247 |  |  | $ | 25,121 |
A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2018 are identified in the following table:
(in thousands) |  | Level 2 |  | Total
Assets: |  |  |  |
Commercial paper |  | $ | 115,141 |  |  | $ | 115,141 |
Asset-backed securities |  | 68,135 |  |  | 68,135 |
Corporate debt securities |  | 240,726 |  |  | 240,726 |
Money market funds |  | 3,082 |  |  | 3,082 |
|  | $ | 427,084 |  |  | $ | 427,084 |
| Level 2 |  | Level 3 |  | Total
Liabilities: |  |  |  |  |  |  |  |
Contingent consideration payable | $ | — |  |  | $ | 19,700 |  |  | $ | 19,700 |
Deferred compensation plan liability | 2,732 |  |  | — |  |  | 2,732 |
| $ | 2,732 |  |  | $ | 19,700 |  |  | $ | 22,432 |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
Schedule of changes in contingent consideration payable | The following table shows the change in the balance of contingent consideration payable for the three and six months ended June 30, 2019 and 2018, respectively:
|  | Three Months Ended June 30, |  | Six Months Ended June 30,
(in thousands) |  | 2019 |  | 2018 |  | 2019 |  | 2018
Balance, beginning of the period |  | $ | 20,767 |  |  | $ | 26,500 |  |  | $ | 28,700 |  |  | $ | 25,400 |
Payment of contingent consideration in stock |  | — |  |  | — |  |  | (9,316 | ) |  | — |
Changes in fair value during the period, included in the Consolidated Statements of Operations |  | 480 |  |  | 300 |  |  | 1,863 |  |  | 1,400 |
Balance, end of the period |  | $ | 21,247 |  |  | $ | 26,800 |  |  | $ | 21,247 |  |  | $ | 26,800 |
Callidus Biopharma Inc |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
Schedule of significant unobservable inputs used in the valuation of the contingent consideration payable | The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB200 Pompe program:
Contingent Consideration Liability |  | Fair Value as of June 30, 2019 |  | Valuation Technique |  | Unobservable Input |  | Range
|  | (in thousands) |  |  |  |  |  |
|  |  |  |  |  | Discount rate |  | 10.1%
Clinical and regulatory milestones |  | $20,999 |  | Probability weighted discounted cash flow |  | Probability of achievement of milestones |  | 75%-78%
|  |  |  |  |  | Projected year of payments |  | 2021-2022

X
- Definition Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2C -URI http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bb) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments. + References No definition available. + Details
Name: | us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |